pharma · Epilepsy · Attention-Deficit/Hyperactivity Disorder (ADHD) · SUPN
SUPERNUS PHARMACEUTICALS
SUPERNUS PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 9715 Key West Ave, Rockville, Maryland 20850, US
- Founded
- 2005
- Employees
- 828
- Programs
- 55
- Drugs
- 25
- Patents
- 68
SUPERNUS PHARMACEUTICALS projects
8 ClinicalTrials.gov programs sponsored by SUPERNUS PHARMACEUTICALS.
SUPERNUS PHARMACEUTICALS has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
100mg SPN-812
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder
1 trial -
APOKYN
SUPERNUS PHARMACEUTICALS, INC.
Parkinson's Disease
2 trials -
Botulinum Toxin Type B
SUPERNUS PHARMACEUTICALS, INC.
Cervical Dystonia
1 trial -
SPN-538
SUPERNUS PHARMACEUTICALS, INC.
Migraine Disorders
1 trial -
SPN-812
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder (ADHD)
1 trial -
SPN-812
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder
3 trials -
SPN-812 (600mg, QD)
SUPERNUS PHARMACEUTICALS, INC.
Healthy Lactating Women
1 trial -
ZULRESSO®
SUPERNUS PHARMACEUTICALS, INC.
Postpartum Depression
1 trial
Frequently asked questions
How many clinical projects does SUPERNUS PHARMACEUTICALS have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.